In conclusion, we demonstrate that modulating S1P1, S1P4 and S1P5 by Etrasimod treatment ameliorates cardinal features associated with progressive NASH. This evidence concerns the gene S1PR1 and metabolic dysfunction-associated steatohepatitis.